46%
of patients receiving JAKAFI achieved ≥50% improvement in TSS at 24 weeks (P<0.0001)1,2†
For US Healthcare Professionals Only
Spleen image is for illustrative purposes only and is not intended to represent actual patient spleen size.
46%
of patients receiving JAKAFI achieved ≥50% improvement in TSS at 24 weeks (P<0.0001)1,2†
80%
of patients on JAKAFI had some improvement in their symptom score.3‡ Most patients receiving placebo had worsening of symptoms1,2
COMFORT=COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment; JAK=Janus kinase; JUMP=JAK Inhibitor RUxolitinib in Myelofibrosis Patients; MF=myelofibrosis; OS=overall survival; SVR=spleen volume reduction; TSS=Total Symptom Score.
References: 1. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation. 2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 3. Data on file. Incyte Corporation. Wilmington, DE.
JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.
JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Please see Full Prescribing Information for JAKAFI/JAKAFI XR.